Shefali Agarwal
Chief Executive Officer presso VALERIO THERAPEUTICS
Patrimonio netto: 76 997 $ in data 31/03/2024
Profilo
Shefali Agarwal is currently the Chairman, President & Chief Executive Officer at Valerio Therapeutics SA, an Independent Director at Fate Therapeutics, Inc., and an Independent Director at Gritstone bio, Inc. She previously served as the Chief Medical Officer at SQZ Biotechnologies Co. from 2017 to 2018 and as the Executive VP, Chief Medical & Development Officer at Epizyme, Inc. from 2018 to 2022.
Dr. Agarwal holds a graduate degree from The Johns Hopkins University, a doctorate degree from Karnataka University, and a graduate degree from Merrick School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FATE THERAPEUTICS, INC.
0.01% | 06/06/2023 | 10 490 ( 0.01% ) | 76 997 $ | 31/03/2024 |
GRITSTONE BIO, INC.
-.--% | 16/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Shefali Agarwal
| Società | Posizione | Inizio |
|---|---|---|
| FATE THERAPEUTICS, INC. | Director/Board Member | 15/07/2019 |
| GRITSTONE BIO, INC. | Director/Board Member | 01/06/2021 |
| VALERIO THERAPEUTICS | Chief Executive Officer | 06/04/2022 |
Precedenti posizioni note di Shefali Agarwal
| Società | Posizione | Fine |
|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 06/04/2022 |
| SQZ BIOTECHNOLOGIES COMPANY | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Formazione di Shefali Agarwal
| The Johns Hopkins University | Graduate Degree |
| Karnataka University | Doctorate Degree |
| Merrick School of Business | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Shefali Agarwal
